The Research Pathology Department in Genentech Research and
Early Development (gRED) is seeking a highly talented, independent
and driven scientist to investigate the cellular phenotypes
responsible for the progression of cancer. This individual will
lead an independent research effort to define the cellular
heterogeneity of cancer, investigate cell-to-cell communication
that drives phenotypes responsible for disease progression, and
identify therapeutic strategies that may counter cancer progression
as well as biomarkers that can inform clinical decision making.
The work will cross biological disciplines but emphasize the use
of advanced tissue technologies (including the full scope of
multiplex detection strategies), computational analytical tools,
informatics and data visualization. The successful candidate will
work with highly collaborative teams generating a wide array of
multi-parametric data including spatial proteomic and
transcriptomic data derived from pre-clinical and clinical samples
(e.g. tissues and biofluids).
* Analyze clinical samples (e.g. tissues, blood) to identify
cellular phenotypes and/or molecular signatures correlating to
and/or responsible for tumor progression.
* Pursue experimental systems that model the disease progression
of interest and enable the quantitative assessment of pathological
phenotypes, therapeutic responses or markers of progression.
* Develop and deploy new methods in digital pathology.
* Collaborate with scientists and pathologists across the
therapeutic areas to design experiments that identify the mechanism
of action underlying disease progression and therapeutic strategies
that counter the process.
* Develop and deploy quantitative analytic strategies including
advanced image analysis, dimensional reduction, and classification
using advanced computational tools such as machine & deep
* Perform large scale informatics using high performance
computing across high dimensional datasets derived through digital
* Mentor colleagues to enable their scientific potential
* Publish in high quality scientific journals and present
externally through presentations at key internal and external
meetings, advisory boards, and conferences
* Ph.D., M.D. or Ph.D/M.D. with relevant postdoctoral experience
in tumor biology, molecular oncology or similar.
* Expertise in bioinformatics and quantitative analytics
including image analysis, big data management, normalization and
clustering methods, dimensional reduction methods, univariate and
multivariate statistical analyses, as well as graphical
presentation of large and complex data sets
* Strong publication record of impactful discoveries that reveal
novel biological pathways and/or advanced technologies to enable
* Experience with performing wet lab experimentation involving
experimental models of cancer progression and collecting multimodal
readouts including phenotypic metrics (cellular appearance &
behavior) and molecular metrics (e.g. RNA & protein).
* Experience in establishing new methods or technologies
* Experience working in a multidisciplinary setting where wetlab
and drylab expertise are fully interoperable.
* Excellent interpersonal skills with demonstrated ability to
work within a team comprised of diverse expertise
* Excellent mentoring skills across all levels
* Excellent oral and written presentation skills
About Research Pathology in Genentech Research and Early
The Department of Pathology provides pathology expertise and
tissue-based analysis to support basic scientific discoveries,
development of drug targets, and biomarkers using both human
tissues and animal models in support of drug development throughout
the pipeline. Pathologists use their scientific and veterinary or
medical backgrounds to integrate data from sources throughout the
company into a coherent analysis of human disease and disease
models. The pathologists' collaborative support of Genentech
scientists includes histopathology interpretive expertise informed
by traditional diagnostic categories as well as by detailed and
expert understanding of molecular and cellular biology. These
activities are enabled by the pathology core (P-core) labs that
include necropsy, clinical pathology, histopathology,
immunohistochemistry / in situ hybridization, a human tissue
biorepository, advanced light microscopy, electron microscopy and
digital pathology, and translational tissue technologies. The
Department provides high quality pathology support to laboratory
and clinical scientists engaged in biomarker
strategy/development/deployment across the drug development
pipeline. These activities can extend into "late stage" clinical
development efforts (Phase III clinical trials).